Anti-CD19 (FMC63) h(41BB-CD3ζ, K4/E4) Conditional CAR, pCDCAR1 (CAR-LC278)

CAR Construction : FMC63 scFv-28ζ

Fig.4 FMC63 and 4G7 CAR T cells effectively responded to CD19‐positive NALM‐6 cells.

Tumor-killing ability of FMC63, 4G7, and FITC CAR T cells against luciferase-expressing NALM-6 and U937. FMC63, 4G7, and FITC CAR T cells (2 × 10^5 cells) were co-cultured with luciferase-expressing NALM-6 (2 × 10^4 cells) or U937 (2 × 10^4 cells) for indicated incubation times at the E:T ratio 10:1. Then, luminescence values were measured.

Kang, Chung Hyo, et al. "Identification of potent CD19 scFv for CAR T cells through scFv screening with NK/T-cell line." International Journal of Molecular Sciences 21.23 (2020): 9163. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-BBζ; FMC63 scFv-28BBζ

Fig.13 Anti-tumor activities of mFMC63-CAR T cells.

Fluorescence images of HeLa-CD19+ expressing mCherry co-cultured with CAR T cells at an E:T ratio of 10:1 as analyzed by fluorescence microscopy.

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-BBζ; FMC63 scFv-28BBζ

Fig.14 Anti-tumor activities of mFMC63-CAR T cells.

Bar graphs represent the percentages of cytotoxicity against HeLa-CD19+ target cells by CAR T cells as measured by crystal violet staining assay.

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-BBζ; FMC63 scFv-28BBζ

Fig.15 Anti-tumor activities of mFMC63-CAR T cells.

Cytotoxicity of Raji cells expressing CD19 antigen by CAR T cells after co-culturing at an E:T ratio of 1:1 for 24 and 48 h.

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-BBζ; FMC63 scFv-28BBζ

Fig.16 IL-2 production in response to coculture of FMC63-CAR cells with Raji cells.

Levels of secreted IL-2 cytokines in the culture supernatants of co-cultured CAR T cells and Raji cells.

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-BBζ; FMC63 scFv-28BBζ

Fig.17 IFN-γ production in response to coculture of FMC63-CAR cells with Raji cells.

Levels of secreted IFN-γ cytokines in the culture supernatants of co-cultured CAR T cells and Raji cells.

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-BBζ; FMC63 scFv-28BBζ

Fig.18 TNF-α production in response to coculture of FMC63-CAR cells with Raji cells.

Levels of secreted TNF-α cytokines in the culture supernatants of co-cultured CAR T cells and Raji cells.

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-28BBζ

Fig.19 The killing activities of mFMC63-CAR4 T cells against Raji cell line.

The killing activities of mFMC63-CAR4 T cells against Raji (CD19+) cells after co-culturing at effector to target (E:T) ratios of 1:1, 2.5:1, and 5:1 for 4 hours.

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-28BBζ

Fig.20 The killing activities of mFMC63-CAR4 T cells against K562-CD19.

The killing activities of mFMC63-CAR4 T cells against K562-CD19+ cells after co-culturing at effector to target (E:T) ratios of 1:1, 2.5:1, and 5:1 for 4 hours.

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-28BBζ

Fig.21 IFN-γ production in the cell culture supernatants of anti-CD19 CAR T cells after activation by culturing with Raji (CD19+) cells.

The levels of IFN-γ production in the cell culture supernatants of anti-CD19 CAR T cells after activation by culturing with Raji (CD19+) cells at an E:T ratio of 5:1 for 24 h were analyzed by enzyme-linked immunosorbent assay (ELISA).

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.

CAR Construction : FMC63 scFv-28BBζ

Fig.22 TNF-α production in the cell culture supernatants of anti-CD19 CAR T cells after activation by culturing with Raji (CD19+) cells.

The levels of TNF-α production in the cell culture supernatants of anti-CD19 CAR T cells after activation by culturing with Raji (CD19+) cells at an E:T ratio of 5:1 for 24 h were analyzed by enzyme-linked immunosorbent assay (ELISA).

Wutti-In, Yupanun, et al. "Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains." Frontiers in Oncology 11 (2022): 802876. Distributed under Open Access license CC BY 4.0, without modification.